drugset / Trial / NCT04406896
The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics
Non-randomizedSequentialOpen-labelOther
Summary
This is a prospective, single-center, open-label, single-dose, Phase 1 study, to assess the effect of mild and moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of selatogrel (ACT-246475).
Timeline
- Start
- 2020-07-22
- Primary completion
- 2020-10-23
- Completion
- 2020-10-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selatogrel | Small molecule | 16 mg | Subcutaneous |
Indications
No indication recorded.